Registry of Lobbyists
Version 5 of 28 (2007-10-25 to 2008-03-14) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
Bayer Inc.
77 Belfield Road Toronto, ON M9W 1G6 Canada |
| Telephone number: | 613-295-8406 |
| Fax number: | 416-240-5292 |
| Responsible officer name and position during the period of this registration: | Philip Blake, President and CEO |
| Description of activities: | Bayer Inc. ("Bayer") is a Canadian subsidiary of Bayer AG, an international research-based group with core businesses in health care, crop science, and innovative materials.Headquartered in Toronto, Ontario, Bayer Inc. operates the Bayer Group's HealthCare and MaterialScience businesses in Canada. Bayer CropScience Inc., headquartered in Calgary, Alberta operates as a separate legal entity in Canada. Together, the companies play a vital role in improving the quality of life for Canadians - producing products that fight diseases, protecting crops and animals, and developing high-performance materials for applications in numerous areas of daily life. |
| The client is a subsidiary of the following parent companies: |
Bayer AG
51368 Leverkusen Germany |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | Greg Ball |
| Position title: | Business Head, Institutional |
| Public offices held: | No |
| Name: | Norma Beauchamp |
| Position title: | Business Head, Community |
| Public offices held: | No |
| Name: | Alan Birrell |
| Position title: | Head, Hematology & Cardiology |
| Public offices held: | No |
| Name: | Ute Bockstegers |
| Position title: | CFO and Head of BAP |
| Public offices held: | No |
| Name: | Joseph Chan |
| Position title: | Senior Regulatory Affairs Associate |
| Public offices held: | No |
| Name: | Shurjeel Choudhri |
| Position title: | Head, Medical & Scientific Affairs |
| Public offices held: | No |
| Name: | Jamie Davis |
| Position title: | Director, Government Affairs and Patient Access (Western Canada) |
| Public offices held: | Yes |
| Name: | Jacqueline DeGagne |
| Position title: | Head - Law and Patents |
| Public offices held: | No |
| Name: | Stefan Freeman |
| Position title: | Head - Animal Health Division |
| Public offices held: | No |
| Name: | Doug Grant |
| Position title: | VP - Corporate Affairs |
| Public offices held: | No |
| Name: | Jim Graziadei |
| Position title: | Head - Diagnostics Division |
| Public offices held: | No |
| Name: | Gord Johnston |
| Position title: | Head - Human Resources |
| Public offices held: | No |
| Name: | Michele Kay |
| Position title: | Director, Regulatory Affairs, Consumer Care Division |
| Public offices held: | Yes |
| Name: | Daniel Lamothe |
| Position title: | Manager, Strategic Partnerships, Hematology Division |
| Public offices held: | No |
| Name: | Reine Larose |
| Position title: | Director - Government Affairs and Patient Access, Quebec, Atlantic Canada |
| Public offices held: | No |
| Name: | Kory McDonald |
| Position title: | Director, Federal Government Affairs |
| Public offices held: | Yes |
| Name: | Paula Moore |
| Position title: | Director, Financial Services |
| Public offices held: | No |
| Name: | Russ Newsome |
| Position title: | Head - Diabetes Care Division |
| Public offices held: | No |
| Name: | Manoj Saxena |
| Position title: | Head, Regulatory Affairs |
| Public offices held: | Yes |
| Name: | Kevin Skinner |
| Position title: | Head - Consumer Care Division |
| Public offices held: | No |
| Name: | Ernie Springnolo |
| Position title: | Country Representative - Bayer MaterialScience |
| Public offices held: | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Agriculture and Agri-Food Canada (AAFC), Environment Canada, Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources and Social Development Canada (HRSDC), Industry Canada, Members of the House of Commons, Natural Resources Canada (NRCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Revenue Canada (RC), Senate of Canada | ||||||||||||||||||||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||||||||||||||||||
| Subject Matter: Areas of Concern: | Agriculture, Consumer Issues, Education, Employment and Training, Environment, Fisheries, Forestry, Government Procurement, Health, Industry, Intellectual Property, International Trade, Labour, Science and Technology, Taxation and Finance | ||||||||||||||||||||||
| Subject Matter: Retrospective: | Bayer Inc. has a number of subject matters of interest related to our health care (animal health, biologicals, consumer care, diagnostics, pharmaceuticals) and material science businesses. These include regulations under the Food and Drugs Act, including Health Canada's regulatory renewal initiative, Canada's environmental policy, including the review of CEPA, consultations relating to the Patented Medicine Prices Review Board's mandate and policies, the federal Science and Technology Strategy and consultations on Canada's budget and taxation, including SR&ED tax credits. | ||||||||||||||||||||||
| Subject Matter: Prospective: | Bayer Inc. has a number of subject matters of interest related to our health care (animal health, biologicals, consumer care, diagnostics, pharmaceuticals) and material science businesses. These include regulations under the Food and Drugs Act, including Health Canada's regulatory renewal initiative, Canada's environmental policy, including the review of CEPA, consultations relating to the Patented Medicine Prices Review Board's mandate and policies, the federal Science and Technology Strategy and consultations on Canada's budget and taxation, including SR&ED tax credits. | ||||||||||||||||||||||
Details Regarding the Identified Subject Matter
|
|||||||||||||||||||||||